awmsg logo



paliperidone palmitate (Xeplion®)


Reference No. 1579

Publication date:
13/11/2012


Appraisal information

paliperidone palmitate (Xeplion®) 50 mg prolonged-release suspension for injection
paliperidone palmitate (Xeplion®) 75 mg prolonged-release suspension for injection
paliperidone palmitate (Xeplion®) 100 mg prolonged-release suspension for injection
paliperidone palmitate (Xeplion®) 150 mg prolonged-release suspension for injection


Company: Janssen-Cilag Ltd
BNF category: Central nervous system
NMG meeting date: 05/09/2012
AWMSG meeting date: 17/10/2012
   
   
Submission Type: Resubmission
Status: Recommended
Advice No: 2512
Ministerial ratification: 09/11/2012

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

Paliperidone palmitate (Xeplion®) prolonged release suspension for injection is recommended as an option for use within NHS Wales for the maintenance treatment of schizophrenia in adult patients stabilised with paliperidone or risperidone; and in selected adult patients with schizophrenia and previous responsiveness to oral paliperidone or risperidone, without prior stabilisation with oral treatment when psychotic symptoms are mild to moderate and a long acting injectable treatment is needed.
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinical Expert (CE) Summary
Download